Revenue: As of FY2026 Q2, the actual value is USD 92.1 M, beating the estimate of USD 90.13 M.

EPS: As of FY2026 Q2, the actual value is USD -0.18.

EBIT: As of FY2026 Q2, the actual value is USD 10.66 M.

The provided reference is a Form 8-K filing by Xeris Biopharma Holdings, Inc. stating that the company issued a press release on August 6, 2026, which contains information about its results of operations and business highlights for the three and six months ended June 30, 2026. However, the detailed financial metrics, operational metrics, cash flow, unique company-specific indicators, and any forward-looking outlook or guidance from this press release are not included within the provided reference text.